Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 10, Pages 1455-1464Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2014.935330
Keywords
enterovirus 71; inactivated EV71 whole virus vaccines; recombinant VP1; synthetic peptide; virus-like particle
Ask authors/readers for more resources
Introduction: Enterovirus 71 (EV71) is an etiological agent that causes severe neurological complications in children. EV71 outbreaks have occurred throughout the Asia-Pacific region, posing a severe global public health threat; however, no specific therapeutic strategy exists for treating EV71-infected children. Areas covered: Five manufacturers have produced inactivated EV71 whole virus vaccines in mainland China, Taiwan, and Singapore, which have completed Phase III (mainland China) and Phase I (Taiwan and Singapore) clinical trials. Various EV71 vaccine candidates are being researched in animal models, including live-attenuated virus vaccine, recombinant VP1 vaccine, VP1-based DNA vaccine, synthetic peptide vaccine and virus-like particle vaccine. In this review, the present situation is summarized, and feasible improvements to the EV71 vaccine are explored. Expert opinion: Although inactivated EV71 vaccines are safe, efficient and elicit strong immune responses to protect adults, children and infants against infection, the quality control of production is critical.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available